HD-OPM Archive

PCSK9 inhibitors: Repatha, Praluent, inclisiran and the new oral pills

What PCSK9 drugs are, how much they lower LDL, what outcome and plaque-imaging trials such as FOURIER, VESALIUS-CV and YELLOW-III show, where the evidence stops (no monotherapy outcome trial), and who the group's admins say should consider them.

14 min read44 group posts cited45 studies discussed3 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • PCSK9 antibodies (Repatha/evolocumab, Praluent/alirocumab) lower LDL-C by roughly 50-60% on top of statins, and the 2025 ESC/EAS update places them after oral options for very-high-risk patients.12
  • VESALIUS-CV (12,000+ high-risk people with no prior heart attack or stroke) found that adding evolocumab cut first major cardiovascular events 25% over about 4.5 years, with LDL falling to a median 45 mg/dL versus 109 mg/dL on placebo.3
  • Every PCSK9 outcome trial cited in the group tested the drug on top of statins; no randomized trial has shown that Repatha or Praluent alone lowers heart attacks or strokes.45
  • In YELLOW-III, adding evolocumab to maximal statin thickened the fibrous cap by over 30% and reduced total plaque (-4.4%) in just 6 months at an average LDL of about 39 mg/dL.67
  • Oral PCSK9 pills are arriving: Merck's Lipfendra was FDA-approved in July 2026 with 56-60% LDL lowering in phase 3, and enlicitide cut LDL 58% in familial hypercholesterolemia.89
  • Side effects and long-term safety are less well known than for statins, so the admins stress reserving these drugs for high-risk people or statin-intolerant patients.1011
In this summary
  1. How much do PCSK9 drugs lower LDL, and where do they fit?
  2. What the outcome trials show
  3. What imaging trials show about plaque
  4. Oral PCSK9 pills and gene editing
  5. Nuances, controversies and common misconceptions
  6. What this means for you
  7. Frequently asked questions
  8. The evidence behind this summary

PCSK9 inhibitors are a newer class of cholesterol-lowering drugs that act on a protein called PCSK9, which normally helps break down the liver's LDL receptors (the "docking stations" that pull LDL cholesterol out of the blood). Blocking PCSK9 leaves more receptors working, so LDL-C (the cholesterol carried in LDL particles) falls sharply. The best-known versions are injectable antibodies: Repatha (evolocumab) and Praluent (alirocumab). Inclisiran is a related injection, described in a shared 2025 ESC/EAS summary as an siRNA given twice a year to help with long-term adherence.1 Oral PCSK9-targeting pills are now reaching the market.8

The group's central message is that PCSK9 drugs are powerful and proven, but proven as an add-on to statins. Louis Nervegna stresses that Repatha and Praluent have only been rigorously shown to lower heart attacks and strokes when combined with statins, and that claims they should replace statins are not supported by outcome data.4 Guidelines keep statins first and add PCSK9 inhibitors when a powerful second drug is needed, with PCSK9 drugs alone recognised as an option mainly for people who cannot take statins.412

This article summarises what the group has shared on how these drugs work, the major trials, plaque imaging studies, the oral newcomers, safety questions, and what admins suggest discussing with a doctor. It reflects group discussion and is not personal medical advice.

50–60%LDL-C reduction with the PCSK9 antibodies Repatha and Praluent1
25%fewer first heart attacks, strokes or coronary deaths when evolocumab was added in VESALIUS-CV3
30%+thicker fibrous cap over plaque after 6 months of evolocumab on top of a statin (YELLOW-III)6
56–60%LDL-C reduction with Lipfendra, an oral PCSK9 pill approved in July 20268

How much do PCSK9 drugs lower LDL, and where do they fit?

A 2025 ESC/EAS guideline update, shared as a graphic by Louis, describes ezetimibe as the first-line oral add-on (about 20% LDL-C reduction), bempedoic acid as an oral option for statin intolerance (about 23% alone, about 38% with ezetimibe), PCSK9 antibodies as high-efficacy injectables (about 50-60%) for very-high-risk patients, and inclisiran as a twice-yearly injection. The summary calls it a stepwise approach from oral combinations to injectables.1 A July 2025 review summarised by Gokhan Can says PCSK9 inhibitors add 59-62% LDL-C reduction on top of statins.2

PCSK9 drugs lower LDL far more than oral add-onsTypical LDL-C reduction by drug, from the 2025 ESC/EAS summary and the phase 3 trials of the oral PCSK9 pills
Ezetimibeabout 20%
Bempedoic acidabout 23%
Bempedoic acid + ezetimibeabout 38%
PCSK9 antibodies (Repatha, Praluent)50–60%
Lipfendra (oral PCSK9 pill)56–60%
Enlicitide (oral PCSK9 pill)58.2%
Figures come from different summaries and trial populations (enlicitide was tested in familial hypercholesterolemia over 24 weeks), so treat them as rough guides. Source: 189
Show data
Value
Ezetimibeabout 20%
Bempedoic acidabout 23%
Bempedoic acid + ezetimibeabout 38%
PCSK9 antibodies (Repatha, Praluent)50–60%
Lipfendra (oral PCSK9 pill)56–60%
Enlicitide (oral PCSK9 pill)58.2%

Guideline targets shared in the group give context for when this is considered.

  • A 2023 JAHA review summarised by Gokhan suggests a goal below 70 mg/dL for high-risk patients and below 55 mg/dL for very-high-risk patients (below 40 mg/dL after recurrent events on statins). It suggests considering ezetimibe and/or a PCSK9 inhibitor in very-high-risk patients who do not reach goal on maximally tolerated statins.12
  • The 2025 ACC/AHA acute coronary syndrome guideline, as summarised by Louis, recommends a non-statin agent (ezetimibe, evolocumab, alirocumab, inclisiran or bempedoic acid) for people on maximally tolerated statins whose LDL is 70 mg/dL or higher, and calls further intensification reasonable at 55 to under 70 mg/dL.13
  • Louis lists the main alternatives for people who cannot tolerate statins as ezetimibe, bempedoic acid, inclisiran, Repatha and Praluent.14

Treatment gaps are large: the July 2025 review summarised by Gokhan says fewer than one in four high-risk ASCVD patients reach the below-55 mg/dL target.2

What the outcome trials show

FOURIER and the "how low" question

FOURIER tested evolocumab added to statins. The 2025 review summarised by Gokhan reports a 15% reduction in primary cardiovascular endpoints at a median LDL-C of 30 mg/dL, and cites a major meta-analysis finding a 21% relative risk reduction per 38.7 mg/dL (1 mmol/L) LDL drop with benefit extending down to levels as low as 21 mg/dL.2 The same post says genetic studies link certain PCSK9 mutations to an 88% reduction in coronary heart disease.2

A Circulation analysis of 5,200+ FOURIER patients with prior ischemic stroke, shared by Gokhan, found that people reaching LDL-C below 40 mg/dL had about 31% fewer major cardiovascular events and 27% fewer recurrent strokes than those at 70 mg/dL or higher, with no excess hemorrhagic stroke even below 20 mg/dL.15 This is an analysis by achieved LDL level, not a randomization to different targets, so it is subject to the usual caveats of such comparisons.

VESALIUS-CV: first events in high-risk primary prevention

VESALIUS-CV (NEJM, 2025) enrolled over 12,000 people (median age 66) who had not had a heart attack or stroke but had established atherosclerosis or high-risk diabetes and an LDL-C of at least 90 mg/dL despite other lipid therapy. Adding evolocumab cut the three-point MACE composite (coronary heart disease death, heart attack or ischemic stroke) by 25% over a median of about 4.5 years. LDL-C fell by nearly 55% to a median 45 mg/dL, against 109 mg/dL in controls.3 A linked summary reports a hazard ratio of 0.75 (95% CI 0.65-0.86), with participants on high-intensity statin therapy in the background.3

ODYSSEY OUTCOMES and the mechanism-independent picture

ODYSSEY OUTCOMES (alirocumab) is named alongside FOURIER and VESALIUS-CV as a landmark trial of PCSK9 inhibitors added to statin therapy, and Louis notes that in FOURIER and ODYSSEY OUTCOMES LDL-C fell below 15-20 mg/dL without impairing steroid hormone production or vitamin D.416

Louis shares a chart from Dr. Daniel Chong combining many LDL-lowering trials. Risk reduction tracked the absolute LDL drop regardless of method; the two PCSK9 inhibitor trials lowered LDL by about 1.9 mmol/L (76 mg/dL) with over 50% lower risk versus placebo in that chart.17 Mendelian randomization data on lifelong LDL variants (including PCSK9) show the same proportional pattern; a 90% lifetime relative reduction from a PCSK9 loss-of-function variant would, by Louis's arithmetic, take a 20% lifetime heart-attack risk to about 2%.18

The chart Louis shared from Dr. Daniel Chong: across fibrates, niacin, ezetimibe, diet, statins, bile acid sequestrants, ileal bypass and PCSK9 inhibitors, the larger the difference in achieved LDL-C, the lower the relative risk of major vascular events; the two PCSK9 inhibitor trials sit furthest along the line.
The chart Louis shared from Dr. Daniel Chong: across fibrates, niacin, ezetimibe, diet, statins, bile acid sequestrants, ileal bypass and PCSK9 inhibitors, the larger the difference in achieved LDL-C, the lower the relative risk of major vascular events; the two PCSK9 inhibitor trials sit furthest along the line.17

Not every LDL-lowering method works. Louis points out that niacin added to high-dose statins and the CETP inhibitors torcetrapib and dalcetrapib lowered LDL but did not reduce major events, which is why outcome trials matter.19

What imaging trials show about plaque

GLAGOV and other trials on top of statins

Gokhan's summary of IVUS trials describes GLAGOV (2016, 968 patients): evolocumab on top of statins reduced percent atheroma volume (PAV) by 0.95% versus a 0.05% increase with statin alone (p<0.001), and total atheroma volume fell 2.9% versus 0.4% over 76 weeks. The ODYSSEY J-IVUS trial (alirocumab, 36 weeks) showed a slight, non-significant reduction.2021 Louis lists GLAGOV, FOURIER and the later YELLOW-III among trials showing plaque reversal.22 Another Gokhan post describes PACMAN-AMI, in which alirocumab produced "triple regression" (less plaque volume, a smaller lipid core and thicker fibrous caps).23

YELLOW-III: six months, statin plus evolocumab

YELLOW-III (JACC Cardiovascular Imaging, 2026) gave 137 patients with chronic coronary disease maximum-dose statins for at least four weeks, then evolocumab 140 mg every two weeks for 26 weeks, with imaging before and after.6 Louis reports these findings.

  • Fibrous cap thickness (OCT) rose by over 30%.6
  • Percent atheroma volume (IVUS) fell by 1.38 absolute points, driven mainly by shrinkage of the soft lipid core.6
  • On his chart, total atheroma volume went from 137.2 to about 131 mm3 (-4.4%) at an average LDL of 39.1 mg/dL.7
  • The "melting butter" label refers to the lipid-core shrinkage on near-infrared imaging.24

Louis notes this is a smaller reversal than some older statin trials, but in only six months, alongside plaque stabilisation.7 An earlier YELLOW study reported that intensive rosuvastatin reduced lipid-core burden within 7-8 weeks.25

Plaque shrank more with evolocumab on top of a statinChange in total atheroma volume (total plaque) on intravascular ultrasound
GLAGOV: statin alone (76 weeks)−0.4%
GLAGOV: evolocumab + statin (76 weeks)−2.9%
YELLOW-III: evolocumab + statin (26 weeks)−4.4%
Different trials and durations: GLAGOV over 76 weeks, YELLOW-III over 26 weeks with no statin-only comparison group. Source: 720
Show data
Value
GLAGOV: statin alone (76 weeks)−0.4%
GLAGOV: evolocumab + statin (76 weeks)−2.9%
YELLOW-III: evolocumab + statin (26 weeks)−4.4%

Evolocumab alone: a small uncontrolled study

A 47-patient imaging study (JACC: Cardiovascular Imaging, 2025; Matthew Budoff among the investigators) followed people on evolocumab for about 18 months, with average LDL near 30 mg/dL. Non-calcified plaque fell from 607.3 to 562.1 microlitres and low-attenuation plaque from 37.1 to 20.4, while total plaque volume was unchanged (716.2 to 710.8) because calcified plaque rose. 37 of 47 participants had some soft-plaque regression.26 Louis says that the study had no randomization or control group, and that while PCSK9 inhibitors likely reverse plaque as monotherapy, rigorous proof of fewer heart attacks as monotherapy is still missing.27 He also compared it with the KETO-CTA study in a post that cautions about comparing different cohorts.28

Change in non-calcified plaque volume for each of the 47 patients in the uncontrolled evolocumab study, ordered from the largest fall to the largest rise: most bars point downward, while a minority of patients saw an increase.
Change in non-calcified plaque volume for each of the 47 patients in the uncontrolled evolocumab study, ordered from the largest fall to the largest rise: most bars point downward, while a minority of patients saw an increase.26

Calcium and the "statin paradox"

Gokhan argues that statins reduce events and plaque burden but accelerate coronary calcification as soft plaque densifies, whereas PCSK9 inhibitors regress plaque with less of a calcific surge. His evidence includes GLAGOV (no significant rise in dense calcium), PACMAN-AMI, and a 2022 randomized trial of 61 people in which alirocumab 75 mg every two weeks added to statins gave median CAC +2.9% versus +10.6% on statins alone over 18 months.232930 A retrospective study (Ikegami, n=120) found annual CAC progression of about 14.3% versus 29.7%.29 Gokhan notes studies are small and larger trials are needed.30

Calcium scores rose more slowly with a PCSK9 inhibitorIncrease in coronary artery calcium (CAC) score, PCSK9 inhibitor (with or instead of a statin) versus statin alone
PCSK9 inhibitorStatin alone
Randomized trial, alirocumab added to statins (61 people, 18 months)2.9%10.6%
Retrospective study, Ikegami (120 people, per year)14.3%29.7%
Small studies; the second is retrospective. Faster calcification on statins may itself reflect plaque stabilising. Source: 2930
Show data
PCSK9 inhibitorStatin alone
Randomized trial, alirocumab added to statins (61 people, 18 months)2.9%10.6%
Retrospective study, Ikegami (120 people, per year)14.3%29.7%

Louis cautions that whether this is an advantage over statins is still debated, since stabilisation by calcification is thought to be part of how statins lower risk.31

Oral PCSK9 pills and gene editing

  • Lipfendra (Merck): Gokhan reports FDA approval (July 2026) of a once-daily oral PCSK9 inhibitor that lowered LDL 56-60% in phase 3 trials.8
  • Enlicitide: a phase 3 trial in 303 adults with heterozygous familial hypercholesterolemia on statins found LDL down 58.2% at 24 weeks (versus +2.6% on placebo) and 55.3% at 52 weeks (versus +8.7%), with safety broadly similar to placebo. The post notes that larger, longer outcome trials are still needed.9
  • AZD0780: a phase 1 trial of 35 people at EAS 2024 cut LDL by at least 30%, with a subanalysis suggesting 78% alongside rosuvastatin; specialists questioned the early data.32
  • Gene editing: Louis warns that experimental PCSK9 gene therapies are not proven safe, noting patient deaths in a trial and adding that this was specific to the gene therapy and not seen in long PCSK9 inhibitor trials.33
  • Berberine: Louis notes berberine inhibits PCSK9 and modestly lowers LDL, far less than the drugs, and suggests it only for low-risk primary prevention.34

Nuances, controversies and common misconceptions

Monotherapy outcome evidence is missing

Louis's central caution is that no randomized outcome trial has shown that PCSK9 inhibitors alone reduce heart attacks, strokes or cardiovascular mortality. The landmark trials (FOURIER, VESALIUS-CV, ODYSSEY OUTCOMES) had virtually all participants on statins, while monotherapy trials in statin-intolerant people (GAUSS for evolocumab, ODYSSEY ALTERNATIVE for alirocumab) measured LDL and tolerability, not events.4 He adds that guidelines recommend monotherapy mainly as backup when first-line therapy fails or is not tolerated.5

Lp(a): lowering the number may not be the goal

PCSK9 inhibitors lower lipoprotein(a) (Lp(a), a genetically set LDL-like particle) by about 27% on average per a meta-analysis cited by Louis.35 Louis argues the HORIZON trial, which lowered Lp(a) massively without reducing MACE, means people taking a PCSK9 drug mainly for Lp(a) should revisit that choice, since statins or statins plus PCSK9 inhibitors have outcome evidence in people with high Lp(a).5 Expert Sam Tsimikas, quoted by Louis, reads Lp(a)HORIZON differently: Lp(a) risk may be managed with LDL-C at or below 65, blood pressure at or below 120 and proven medicines, and in his clinic about 75% of patients take a statin, 50% ezetimibe and 50% a PCSK9 inhibitor.36

Side effects and the track record

Louis rejects the claim that PCSK9 inhibitors lack significant side effects. The manufacturer lists flu-like symptoms, back pain and high blood sugar among the most common, and long-term effects are less known than for statins, which he says is why guidance reserves them for high-risk or statin-intolerant patients.10 He personally takes a low-dose statin because statin side effects are known after decades, while newer drugs may have undiscovered ones; he labels this his own rationale.11 Gokhan describes feeling good after switching from ezetimibe to Repatha alongside pitavastatin, but presents this as personal experience.37 He also says that on rosuvastatin plus ezetimibe his LDL was not very different from low-dose rosuvastatin alone and that he was exploring a PCSK9 inhibitor.38

Very low LDL, brain and hormones

  • Louis says PCSK9 inhibitors lower cholesterol only in the circulation, not the brain, because the brain makes its own cholesterol and blood cholesterol cannot cross the blood-brain barrier.3940
  • He also says tissues, including the adrenals and gonads, need only tens of milligrams of cholesterol per day from blood, and that trials reaching LDL-C below 15-20 mg/dL did not impair hormone production or vitamin D.16
  • The July 2025 review summarised by Gokhan reports that cognitive decline (evaluated in EBBINGHAUS) and hemorrhagic stroke (number needed to harm 3,333) concerns are not supported by large-scale data.2

Diabetes and inflammation

A review shared by Gokhan lists PCSK9 inhibitors alongside ezetimibe and pitavastatin as ways to lower LDL while limiting glycemic harm compared with statins.41 On inflammation, a shared meta-analysis found that PCSK9 inhibitors did not lower hsCRP: its illustration shows a slight rise of about 6%, against falls of 17.3% for statins and 3.2% for ezetimibe, although Louis's summary of it lists a 6% reduction.42

Aging claims are speculative

Louis shared GeroScience reviews proposing PCSK9 as a regulator of cardiometabolic aging, and suggested that the drugs may be treating aging in the heart and liver. The claim is speculative and an emerging research area.4344

What this means for you

These points reflect the group's discussion; discuss your own situation with your doctor.

  • If you are already on a maximally tolerated statin and still above your goal, the guideline summaries shared in the group list PCSK9 antibodies as an option for very-high-risk patients, after oral add-ons such as ezetimibe.11213
  • The strongest outcome evidence is for adding PCSK9 inhibitors to statins (FOURIER, ODYSSEY OUTCOMES, VESALIUS-CV).34
  • If you cannot take statins, the group lists PCSK9 inhibitors as an alternative, but the admins point out that this rests on LDL-lowering data rather than outcome trials.414
  • Louis argues against using a PCSK9 inhibitor as first-line monotherapy for primary prevention, and against taking one mainly to lower Lp(a).5
  • In the analyses shared, lower achieved LDL tracked with fewer events, down to the very low levels tested.215
  • Oral options and twice-yearly injections may help people who dislike self-injecting or struggle with adherence.19
  • Treat gene editing and supplements such as berberine as different categories from approved drugs.3334

Frequently asked questions

Do PCSK9 inhibitors prevent heart attacks?

Yes, when added to statins: VESALIUS-CV showed a 25% reduction in first major events, and FOURIER and ODYSSEY OUTCOMES are cited as outcome trials on statin background.34 As a stand-alone treatment, there is no randomized outcome trial.5

Can PCSK9 inhibitors replace statins?

Louis says influencers have overstated this. The drugs might work better, but there are no outcome data showing it, which is why guidelines keep statins first-line.4

Do they reverse plaque?

On top of statins, yes in imaging trials such as GLAGOV (total atheroma volume -2.9% over 76 weeks) and YELLOW-III (fibrous cap up over 30% and plaque down in 6 months).620 A small uncontrolled 47-patient study showed soft-plaque reduction at LDL near 30 mg/dL.26 Plaque imaging is a surrogate, not a heart-attack outcome.27

Is very low LDL safe?

The July 2025 review summary says concerns such as hemorrhagic stroke, cognitive decline and hormone disruption are not supported by large-scale data, and the FOURIER stroke analysis found no excess hemorrhagic stroke below 20 mg/dL.215 Louis cautions that long-term effects of newer drugs are still less known than for statins.10

What are the new pills?

Lipfendra (FDA-approved July 2026) and enlicitide are oral PCSK9 inhibitors that cut LDL by roughly 56-60% in phase 3 trials, while AZD0780 is at an earlier phase 1 stage. Outcome trials for the pills are still pending.8932

The evidence behind this summary45 studies · 3 meta-analyses · 23 trials · 1 MR · 4 observational

The 44 group posts cited above discuss 45 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 3Randomized trials 23Mendelian randomization 1Observational studies 4Reviews & guidelines 10Other sources 4

Strongest evidence discussed

All 45 studies and sources
Sources from the group (44)
  1. 2025 ESC/EAS update: where ezetimibe, bempedoic acid, PCSK9 drugs and inclisiran fit Louis Nervegna · Oct 19, 2025 · Facebook
  2. Review: aggressive LDL lowering outweighs theoretical risks, yet few reach <55 mg/dL Gokhan Can · Oct 28, 2025 · Facebook
  3. VESALIUS-CV: Repatha cut first heart attack or stroke 25% in high-risk primary prevention Gokhan Can · Nov 08, 2025 · Facebook
  4. No trial has shown PCSK9 inhibitors lower heart attack risk without statins Louis Nervegna · Aug 13, 2026 · Facebook
  5. No trial shows PCSK9 inhibitor monotherapy cuts heart attacks; HORIZON undermines Lp(a) Louis Nervegna · Oct 31, 2026 · Facebook
  6. YELLOW-III: statin plus evolocumab thickened fibrous caps over 30% in 6 months Louis Nervegna · Mar 22, 2026 · Facebook
  7. YELLOW-III reversed total atheroma volume 4.4% in 6 months at LDL of about 39 mg/dL Louis Nervegna · Mar 23, 2026 · Facebook
  8. Merck's oral PCSK9 pill Lipfendra approved by FDA, cut LDL 56-60% in Phase 3 Gokhan Can · Jul 16, 2026 · Facebook
  9. Oral PCSK9 inhibitor enlicitide cut LDL 58% in familial hypercholesterolemia Louis Nervegna · Dec 01, 2025 · Facebook
  10. PCSK9 inhibitors like Repatha have real side effects and a shorter safety record Louis Nervegna · Apr 15, 2024 · Facebook
  11. Why Louis takes a low-dose statin: known side effects beat unknown ones of newer drugs Louis Nervegna · May 09, 2024 · Facebook
  12. Evolving LDL-C management (JAHA 2023): risk categories, thresholds and treatment goals Gokhan Can · Nov 25, 2023 · Facebook
  13. 2025 ACC/AHA ACS guideline: high-intensity statin plus a non-statin if LDL is 70 or above Louis Nervegna · Feb 27, 2025 · Facebook
  14. Statin-intolerant? Options include ezetimibe, bempedoic acid, inclisiran, PCSK9 antibodies Louis Nervegna · May 30, 2026 · Facebook
  15. FOURIER stroke analysis: LDL below 40 mg/dL cut major events ~31% and recurrent stroke 27% Gokhan Can · Nov 13, 2025 · Facebook
  16. Tissues make their own cholesterol: even very low LDL-C does not impair hormone production Louis Nervegna · Sep 17, 2026 · Facebook
  17. Every LDL-lowering method lowers cardiac risk in proportion to the LDL reduction achieved Louis Nervegna · Dec 08, 2024 · Facebook
  18. Mendelian randomization: lifelong lower LDL tracks linearly with lower heart disease risk Louis Nervegna · Oct 10, 2026 · Facebook
  19. Lowering LDL does not guarantee fewer events: niacin and CETP inhibitors failed on MACE Louis Nervegna · Aug 14, 2026 · Facebook
  20. PCSK9 inhibitors on top of statins regressed plaque in GLAGOV and PRECISE-IVUS Gokhan Can · Dec 25, 2023 · Facebook
  21. Plaque reduction: statins, PCSK9 inhibitors and ezetimibe have the strongest evidence Gokhan Can · May 18, 2024 · Facebook
  22. Trials showing plaque regression: ASTEROID, GLAGOV, FOURIER, HUYGENS, YELLOW-III Louis Nervegna · Aug 12, 2026 · Facebook
  23. PCSK9 inhibitors regress plaque without the calcification surge seen with statins Gokhan Can · Jan 01, 2026 · Facebook
  24. YELLOW-III 'melting butter' sign: lipid core shrinks and fibrous cap thickens in 6 months Louis Nervegna · Mar 22, 2026 · Facebook
  25. YELLOW trials: intensive rosuvastatin cut lipid-core plaque within 7-8 weeks Louis Nervegna · Aug 15, 2026 · Facebook
  26. Repatha for 18 months reduced non-calcified plaque on CT angiography in a 47-patient study Louis Nervegna · Mar 02, 2026 · Facebook
  27. Repatha alone reversed soft plaque in 37 of 47 patients over 18 months at LDL near 30 Louis Nervegna · Nov 13, 2026 · Facebook
  28. Keto-CTA plaque progression vs plaque regression on Repatha in Budoff's other study Louis Nervegna · Apr 09, 2025 · Facebook
  29. PCSK9 inhibitor plus statin nearly halted coronary calcium progression versus statin alone Gokhan Can · Dec 01, 2025 · Facebook
  30. Alirocumab plus statin slowed coronary calcium progression: +2.9% vs +10.6% at 18 months Gokhan Can · Jan 01, 2026 · Facebook
  31. PCSK9 inhibitors regress soft plaque without the calcification surge seen with statins Louis Nervegna · Jul 02, 2026 · Facebook
  32. Oral PCSK9 inhibitor AZD0780 cut LDL at least 30% in phase 1, 78% with rosuvastatin Gokhan Can · Jun 28, 2024 · Facebook
  33. PCSK9 gene-editing therapy may not be safe yet; patient deaths occurred in a trial Louis Nervegna · Mar 18, 2025 · Facebook
  34. Berberine inhibits PCSK9 and modestly lowers LDL, far less than PCSK9 drugs Louis Nervegna · Jun 21, 2025 · Facebook
  35. PCSK9 inhibitors lower Lp(a) by an average of 27%, per meta-analysis Louis Nervegna · Sep 13, 2025 · Facebook
  36. Tsimikas: Lp(a) risk can be managed with LDL under 65 and tight risk-factor control Louis Nervegna · Nov 10, 2026 · Facebook
  37. Admin's experience adding ezetimibe, pitavastatin and Repatha after statin intolerance Gokhan Can · Jan 08, 2026 · Facebook
  38. Admin asks cardiologist about rosuvastatin raising insulin, and pitavastatin plus PCSK9i Gokhan Can · Dec 30, 2025 · Facebook
  39. PCSK9 inhibitors lower circulating cholesterol only, not brain cholesterol Louis Nervegna · Mar 09, 2025 · Facebook
  40. Only lipophilic statins like atorvastatin enter the brain; PCSK9 drugs and ezetimibe don't Louis Nervegna · Oct 18, 2025 · Facebook
  41. Limiting diabetes risk on LDL-lowering drugs: statin risk is modest, alternatives exist Gokhan Can · Nov 26, 2025 · Facebook
  42. Statins, bempedoic acid, ezetimibe, fibrates and PCSK9 inhibitors all lower hsCRP Louis Nervegna · Dec 28, 2025 · Facebook
  43. PCSK9 inhibition may slow cardiometabolic aging beyond lowering cholesterol Louis Nervegna · Dec 21, 2023 · Facebook
  44. Review: PCSK9 emerges as a regulator of cardiometabolic aging in heart and liver Louis Nervegna · Jan 31, 2024 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary